HRV Pharma has unveiled RIKO, an in-house reasoning engine that the company says is designed to support pharmaceutical decision-making across sourcing, compliance and supply chain management.
The platform has been built from seven years of operational experience and, according to the company, draws on proprietary decisions generated within a network of more than 50 FDA- and EU-GMP-certified manufacturing partners and customers in 55 countries. HRV Pharma says this distinguishes...
Continue Reading This Article
Enjoy this article as well as all of our content, including reports, news, tips and more.
By registering or signing into your SRM Today account, you agree to SRM Today's Terms of Use and consent to the processing of your personal information as described in our Privacy Policy.
RIKO from conventional enterprise AI tools trained on public data, because the system has been shaped by real commercial, regulatory and technical outcomes rather than general datasets.
The company says RIKO uses ten federated reasoning models that continuously retrain through a shared contextual architecture. In practice, HRV Pharma says the system is intended to identify emerging problems earlier in the decision-making process, whether those relate to chemistry, supplier reliability, regulatory history, manufacturing capability or commercial fit.
One of the platform’s headline claims is a 94 per cent predictive accuracy rate in spotting potential nitrosamine-related risk patterns during early assessment. HRV Pharma says this has allowed technical teams to investigate issues before they reach more conventional review stages. It also says supplier qualification cycles that once took four to eight weeks have been cut by 85 per cent, while human oversight remains in place for final approval decisions.
The company adds that inbound commercial enquiries are screened automatically on first review, with opportunity scoring, supplier matching and commercial prioritisation completed in under two seconds. HRV Pharma says the aim is to reduce delays and surface risks before sourcing commitments or licensing decisions are finalised.
The launch fits into a broader argument the company has been making about the future of pharmaceuticals. In recent commentary published on its own newsroom, founder and chief executive Hari Kiran Chereddi has said the industry is moving away from a model defined primarily by manufacturing capacity and towards one shaped by intelligence-led decisions made much earlier in the development process. He has argued that the crucial choices increasingly involve molecule selection, market sequencing, regulatory pathways and supply chain design long before a product reaches commercial production.
HRV Pharma also said the wider sector is embracing artificial intelligence across research, quality, regulatory work and supply chain operations, but that the deeper competitive advantage will come from institutional knowledge built through experience. Sowjanya Varma, the company’s chief information officer, said RIKO was built to “compound judgment” rather than merely automate tasks, and that each regulatory interaction, supplier assessment, deviation and technical evaluation should make the system more capable over time.
The company presents RIKO as part of a wider digital shift in pharma, one that aims to make compliance and risk control more proactive than reactive. It says the platform is intended to support transparency, shorten supplier onboarding and help prevent quality or regulatory problems before they affect patients or products.
Source: Noah Wire Services
